| Autor: |
Vilaseca, Andreu, Do, Le-Duy, Miske, Ramona, Ciano-Petersen, Nicolás Lundahl, Khatib, Laura, Villagrán-García, Macarena, Farina, Antonio, Rogemond, Véronique, Komorowski, Lars, Gonçalves, David, Joubert, Bastien, Honnorat, Jérôme |
| Předmět: |
|
| Zdroj: |
Journal of Neurology; Sep2023, Vol. 270 Issue 9, p4533-4537, 5p |
| Abstrakt: |
3Clinical presentation of patients with AP3B2-IgG antibodies obtained from the 11 patients previously reported (data not available for one patient) and the two patients described herein In previously reported cases, none of the five patients who received immunotherapy improved, but three of them remained neurologically stable [[6]]. The previously published patients had either cerebellar ataxia ( I n i = 5) or peripheral neuropathy ( I n i = 5), with or without spinal cord involvement (cerebellar ataxia with spinal cord impairment, I n i = 2, and peripheral neuropathy with spinal cord impairment, I n i = 3) with a subacute clinical course, reaching a plateau after a few weeks (Fig. 2Cell-based binding A and immunoblot B assays demonstrating positivity for anti-AP3B2 antibodies in the cerebrospinal fluid (CSF) of patient 1 and serum of patient 2 In this study, we present two patients with progressive cerebellar ataxia and AP3B2-IgG, including the first pediatric patient ever reported. The cerebrospinal fluid (CSF) of a patient (patient 1) with atypical neuropil staining on a rat brain indirect immunofluorescence assay was used to immunoprecipitate candidate autoantigens as previously reported [[7]], leading to the identification of AP3B2 as the likely antigen. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink